{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-014938","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.554473+00:00","generated_at":"2026-06-21T23:05:48.366383+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Monopar Q3 net loss $2.4M ($0.19/share); cash $14.3M; Validive interim analysis Q1 2023","bullets":["Net loss of $2.4M ($0.19 per share) vs. $2.5M ($0.20) in Q3 2021; R&D $1.73M, G&A $0.68M.","Cash and equivalents $14.3M; expects to fund VOICE Phase 2b and camsirubicin Ph1b through Nov 2023.","Validive VOICE trial: 73 active sites, >130 patients dosed; Phase 2b enrollment complete; Phase 3 enrollment started.","Blinded interim analysis of Validive Phase 2b data expected to be reported in Q1 2023.","Camsirubicin Ph1b data to be presented at CTOS Nov 16-19; MNPR-202 preclinical data at ASH Dec 10-13."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-014938","json":"https://secwatch.observer/filing/0001654954-22-014938.json","markdown":"https://secwatch.observer/filing/0001654954-22-014938.md","text":"https://secwatch.observer/filing/0001654954-22-014938.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422014938/0001654954-22-014938-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422014938/mnpr_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:05:48.366383+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"af31f4dea6ede5971be0c98b1202036885b88983","claim":"Monopar Therapeutics reported third quarter ended September 30, 2022 results: net income $2.4 million or $0.19 per share, EPS $0.19 per share.","evidence_excerpt":"Monopar Therapeutics Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645469/000165495422014938/0001654954-22-014938-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Net income","value":"$2.4 million or $0.19 per share"},{"label":"EPS","value":"$0.19 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}